Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Area of Science:

• Clinical pharmacology
• Translational sciences
• Health equity research

Background:

• The American Society for Clinical Pharmacology and Therapeutics (ASCPT) aims to reduce health disparities.
• The Development, Regulatory, and Outcomes (DRO) network within ASCPT focuses on advancing pharmacoequity.
• Pharmacoequity ensures equitable access to high-quality, evidence-based therapies for all individuals, irrespective of race, ethnicity, geography, or socioeconomic status.

Purpose of the Study:

• To highlight the contributions of the ASCPT DRO network in advancing global pharmacoequity.
• To identify priority areas for improving health outcomes and reducing disparities.

Main Methods:

• This is a perspective piece, not an empirical study.
• It involves a review and synthesis of the ASCPT DRO network's initiatives and goals.
• Focuses on the conceptual framework of pharmacoequity.

Main Results:

• The ASCPT DRO network is actively working towards the goal of pharmacoequity.
• Key contributions and ongoing efforts are detailed.
• Priority areas for future work are outlined to foster equitable health outcomes.

Conclusions:

• Advancing pharmacoequity is crucial for reducing health disparities.
• The ASCPT DRO network plays a significant role in this mission.
• Continued focus on identified priority areas will be essential for achieving equitable health outcomes globally.